Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of ICP-022 versus chlorambucil + rituximab in previously untreated CLL/SLL
CTR20201980Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Innovent Biologics. Started Jan 2021; status: active.
02
Drugs
orelabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20201980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201980.